Histone deacetylase inhibitors as a treatment of TRAIL-resistant cancers

No Thumbnail Available
File version
Author(s)
Neuzill, J
Andera, L
Gabrielli, B
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Sluyser, M.
Date
2005
Size
File type(s)
Location
License
Abstract

Histone deacetylas inhibitors (HDIs) are a novel prospective group of potential anti-cancer agents, some of them being tested in a clinical setting. The major mode of action of these compounds is inhibition of the cell cycle transition and, consequently, differential regulation of a number of genes necessary for cell proliferation, while favouring expression of genes rather associated with anti-proliferative pathways and with cell death signalling. This implies a possible role of HDIs in adjuvant treatment of tumours resistant to other agents, operating via a different molecular mechanism. The TNF-related apoptosis-inducing ligant (TRAIL) is a promising immunological inducer of apoptosis efficient against a variety of tumours with a remarkably selective mode of action. However, some malignancies are resistant to TRAIL treatment. In this paper, we review our current knowledge on HDI-mediated sensitisation of TRAIL-non-responsive tumours to this apoptogen and suggest a future clinical potential of HDIs and TRAIL in cancer management.

Journal Title
Conference Title
Book Title
Application of apoptosis to cancer treatment
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Multi-Disciplinary
Persistent link to this record
Citation
Collections